These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 26196195)

  • 1. Nonacog alfa: an analysis of safety data from six prospective clinical studies in different patient populations with haemophilia B treated with different therapeutic modalities.
    Rendo P; Smith L; Lee HY; Shafer F
    Blood Coagul Fibrinolysis; 2015 Dec; 26(8):912-8. PubMed ID: 26196195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective registry of European haemophilia B patients receiving nonacog alfa, recombinant human factor IX, for usual use.
    Berntorp E; Keeling D; Makris M; Tagliaferri A; Male C; Mauser-Bunschoten EP; Musso R; Roca CA; Hassoun A; Kollmer C; Charnigo R; Baumann J; Rendo P
    Haemophilia; 2012 Jul; 18(4):503-9. PubMed ID: 22044794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A national French noninterventional study to assess the long-term safety and efficacy of reformulated nonacog alfa.
    Lambert T; Rothschild C; Volot F; Borel-Derlon A; Trossaërt M; Claeyssens-Donadel S; Attal S
    Transfusion; 2017 Apr; 57(4):1066-1071. PubMed ID: 28337764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First open-label, single-arm, prospective study of real-world use of FIX replacement therapy in a predominantly pediatric hemophilia B population in China.
    Yang R; Wu R; Sun J; Sun F; Rupon J; Huard F; Korth-Bradley JM; Xu L; Luo B; Liu YC; Rendo P
    Medicine (Baltimore); 2021 May; 100(21):e26077. PubMed ID: 34032739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, Efficacy, and Safety of Nonacog Alfa in Previously Treated Patients with Moderately Severe to Severe Hemophilia B.
    Korth-Bradley JM; Rendo P; Smith L; Altisent C
    Clin Ther; 2016 Apr; 38(4):936-44. PubMed ID: 26969334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B.
    Kavakli K; Smith L; Kuliczkowski K; Korth-Bradley J; You CW; Fuiman J; Zupančić-Šalek S; Abdul Karim F; Rendo P
    Haemophilia; 2016 May; 22(3):381-8. PubMed ID: 26823276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postmarketing safety and effectiveness of recombinant factor IX (nonacog alfa) in Japanese patients with haemophilia B.
    Fukutake K; Taki M; Matsushita T; Sakai M; Takata A; Yamaguchi H; Karumori T
    Haemophilia; 2019 Jul; 25(4):e247-e256. PubMed ID: 31168882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects.
    Valentino LA; Rusen L; Elezovic I; Smith LM; Korth-Bradley JM; Rendo P
    Haemophilia; 2014 May; 20(3):398-406. PubMed ID: 24418368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm™4).
    Young G; Collins PW; Colberg T; Chuansumrit A; Hanabusa H; Lentz SR; Mahlangu J; Mauser-Bunschoten EP; Négrier C; Oldenburg J; Patiroglu T; Santagostino E; Tehranchi R; Zak M; Karim FA
    Thromb Res; 2016 May; 141():69-76. PubMed ID: 26970716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of nonacog alfa for the treatment of haemophilia B in children younger than 6 years of age in a routine clinical care setting: the EUREKIX registry study.
    Liesner R; Andersson NG; Frisk T; Santagostino E; Schulz M; Young L; Giordano P; Tagliaferri A
    Haemophilia; 2021 Jan; 27(1):e60-e68. PubMed ID: 33277961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX.
    Escobar MA; Tehranchi R; Karim FA; Caliskan U; Chowdary P; Colberg T; Giangrande P; Giermasz A; Mancuso ME; Serban M; Tsay W; Mahlangu JN
    Haemophilia; 2017 Jan; 23(1):67-76. PubMed ID: 27480487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis.
    Martinowitz U; Shapiro A; Quon DV; Escobar M; Kempton C; Collins PW; Chowdary P; Makris M; Mannucci PM; Morfini M; Valentino LA; Gomperts E; Lee M
    Haemophilia; 2012 Nov; 18(6):881-7. PubMed ID: 22764744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of a recombinant factor IX (Bax326) in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open-label, uncontrolled, multicentre, phase III study.
    Windyga J; Lissitchkov T; Stasyshyn O; Mamonov V; Ghandehari H; Chapman M; Fritsch S; Wong WY; Pavlova BG; Abbuehl BE
    Haemophilia; 2014 Sep; 20(5):651-8. PubMed ID: 24697870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement in health-related quality of life in patients with haemophilia B treated with nonacog beta pegol, a new extended half-life recombinant FIX product.
    Chowdary P; Kearney S; Regnault A; Hoxer CS; Yee DL
    Haemophilia; 2016 Jul; 22(4):e267-74. PubMed ID: 27352908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials.
    Oldenburg J; Carcao M; Lentz SR; Mahlangu J; Mancuso ME; Matsushita T; Négrier C; Clausen WHO; Ehrenforth S; Young G
    Haemophilia; 2018 Nov; 24(6):911-920. PubMed ID: 30248217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonacog Beta Pegol: A Review in Haemophilia B.
    Syed YY
    Drugs; 2017 Dec; 77(18):2003-2012. PubMed ID: 29124682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B.
    Windyga J; Lissitchkov T; Stasyshyn O; Mamonov V; Rusen L; Lamas JL; Oh MS; Chapman M; Fritsch S; Pavlova BG; Wong WY; Abbuehl BE
    Haemophilia; 2014 Jan; 20(1):15-24. PubMed ID: 23834666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial.
    Carcao M; Zak M; Abdul Karim F; Hanabusa H; Kearney S; Lu MY; Persson P; Rangarajan S; Santagostino E
    J Thromb Haemost; 2016 Aug; 14(8):1521-9. PubMed ID: 27174727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safe switching from a pdFIX (Immunine®) to a rFIX (Bax326).
    Solano Trujillo MH; Stasyshyn O; Rusen L; Serban M; Lamas JL; Perina FG; Urasinski T; Oh M; Knowlton WB; Valenta-Singer B; Pavlova BG; Abbuehl B
    Haemophilia; 2014 Sep; 20(5):674-81. PubMed ID: 24720694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant long-acting glycoPEGylated factor IX (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials.
    Negrier C; Young G; Abdul Karim F; Collins PW; Hanabusa H; Colberg T; Goldman B; Walsh CE;
    Haemophilia; 2016 Jul; 22(4):507-13. PubMed ID: 26936227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.